Trials / Recruiting
RecruitingNCT06484777
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
An Open-label, Multi-center Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of SHR-9539 Injection in Patients With Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-9539 for injection | SHR-9539 for dose escalation/dose extension |
Timeline
- Start date
- 2024-08-07
- Primary completion
- 2027-07-31
- Completion
- 2027-07-31
- First posted
- 2024-07-03
- Last updated
- 2026-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06484777. Inclusion in this directory is not an endorsement.